Trial site

Linfen Central Hospital

Linfen, 041000, ChinaNot linked to an institution yet

27running trials
11closed trials

The trials here

What the 39 trials at this site are about, from their registry records.

Conditions: Stroke16 trials
Lupus (SLE)8 trials
COPD2 trials
Coronary artery disease2 trials
Depression2 trials
Gastric and oesophageal cancer2 trials
Gout2 trials
Heart failure2 trials
Psoriasis2 trials
Psoriatic arthritis2 trials
Hepatitis B1 trial
Liver and biliary tract cancer1 trial
Phase: Phase 320 trials
Phase 216 trials
Phase 11 trial
Phase 1/21 trial
Status: Recruiting16 trials
Completed11 trials
Not yet recruiting8 trials
Active, not recruiting3 trials
Suspended1 trial
Lead sponsor: Beijing Tiantan Hospital6 trials
Boehringer Ingelheim4 trials
Janssen Research & Development, LLC4 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 trials
and 20 more

Running trials

Not yet recruiting
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155· Phase 2· Shanghai Escugen Biotechnology Co., Ltd· Source
Contact: Qiuyue Shan Qiuyue shan
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Contact: Yan Dong (principal investigator)
Recruiting
A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
NCT07406035· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Shuhua Qiang, Bachelor
Recruiting
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
NCT07509892· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Shuhua Qiang, Bachelor
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450· Phase 2· Takeda· Source
Contact: Hongguo Dai (principal investigator)
Not yet recruiting
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
NCT07242599· Phase 3· Beijing Tiantan Hospital· Source
Contact: Hongguo Dai
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014· Phase 2· Eisai Co., Ltd.· Source
Recruiting
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
NCT07453004· Phase 2· TJ Biopharma Co., Ltd.· Source
Contact: Shuhua Qiang
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986· Phase 2· Hangzhou Sumgen Biotech Co., Ltd.· Source
Contact: Shuhua Qiang, Bachelor
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
NCT07311200· Phase 2· InventisBio Co., Ltd· Source
Contact: Shuhua Qiang
Recruiting
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
NCT07520565· Phase 3· Biocells (Beijing) Biotech Co.,Ltd· Source
Contact: Hongguo Dai
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Xuehong Zhao, Doctor
Recruiting
Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
NCT07241520· Phase 3· Shanghai Hutchison Pharmaceuticals Limited· Source
Contact: Hongguo Dai, Master
Recruiting
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
NCT07279493· Phase 2· Kunming Pharmaceuticals, Inc.· Source
Contact: Duo Gao, bachelor
Recruiting
Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy
NCT07581210· Phase 2· Shanghai QuietD Biotechnology Co., Ltd.· Source
Contact: Hongguo Dai
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Yuefeng Chai
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06789289· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Recruiting
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042· Phase 1/2· Sinocelltech Ltd.· Source
Contact: Shuhua Qiang
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
NCT06157502· Phase 3· Beijing Tiantan Hospital· Source
Contact: Hongguo Dai
Recruiting
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source
Contact: Hongguo Dai
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Stroke9 recruiting
Lupus (SLE)8 recruiting
Heart failure2 recruiting
Depression1 recruiting
Gastric and oesophageal cancer1 recruiting
Gout1 recruiting
Hepatitis B1 recruiting
Liver and biliary tract cancer1 recruiting
Psoriasis1 recruiting
Psoriatic arthritis1 recruiting

Closed trials

Completed
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229· Phase 2· Atom Therapeutics Co., Ltd· Source
Completed
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
NCT07091929· Phase 1· Beijing Sungen Biomedical Technology Co., Ltd· Source
Completed
Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder
NCT07253207· Phase 3· Zhejiang Huahai Pharmaceutical Co., Ltd.· Source
Completed
Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke
NCT06316570· Phase 3· Beijing Tiantan Hospital· Source
Completed
Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5
NCT06196320· Phase 3· Beijing Tiantan Hospital· Source
Completed
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
NCT06202378· Phase 2· Shanghai Hutchison Pharmaceuticals Limited· Source
Completed
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
NCT05836740· Phase 3· Beijing Tiantan Hospital· Source
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· Phase 3· Janssen Research & Development, LLC· Source
Completed
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
NCT05700591· Phase 3· Tasly Biopharmaceuticals Co., Ltd.· Source
Completed
ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)
NCT05507645· Phase 3· Beijing Tiantan Hospital· Source
Completed
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801· Phase 3· Amgen· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error